13685NRG-GI008-NCT05174169OpenColon Adjuvant Chemotherapy Based on Evaluation of Residual DiseaseThis Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
NRG-GI008NCT05174169Industrial; NationalAdultTreatmentDevice: Signatera test
Drug: mFOLFOX6 3-6 month
Drug: CAPOX 3 month
Drug: mFOLFIRINOX
Drug: mFOLFOX6 6 month
Drug: CAPOX 6 monthII/IIINationalColonThis study investigates the following conditions or diseases: Stage III Colon Cancer
Weinberg, BenjaminGeorgetown University Medical Center : Susan Lawrence; Lombardi Comprehensive Cancer Center : Susan Lawrence; Medstar Franklin Square Medical Center; Medstar Good Samaritan Hospital; Medstar Montgomery Medical Center; Medstar Washington Hospital CenterGastrointestinalOncology GroupLombardi Comprehensive Cancer Center (LCCC)- 17105Susan LawrenceSusan Lawrencesl2328@georgetown.edu
2026.1.0 Build 16 <a href="https://advarra.com" target="_blank">© 2026 Advarra, Inc.</a>